| Literature DB >> 23706094 |
Jason R Jaggers1, Wesley Dudgeon, Steven N Blair, Xuemei Sui, Stephanie Burgess, Sara Wilcox, Gregory A Hand.
Abstract
BACKGROUND: While combination antiretroviral therapy has extended the life expectancy of those infected with human immunodeficiency virus (HIV), there is a high prevalence of comorbidities that increase the risk of cardiovascular morbidity and mortality among people living with HIV/AIDS (PLWHA). The side effects associated with antiretroviral therapy (ART) lead to multiple metabolic disorders, making the management of these metabolic issues and risk of cardiovascular disease (CVD) in those treated with ART a critical issue. Clinical research trials, primarily clinical exercise, rarely include this population due to unique challenges in research methods with underserved minority populations living with a life threatening illness like HIV/AIDS. This paper describes the rationale and design of a randomized clinical trial evaluating the feasibility of a home-based exercise program designed to increase physical activity (PA) and reduce the risk of CVD in PLWHA. METHODS/Entities:
Mesh:
Year: 2013 PMID: 23706094 PMCID: PMC3668143 DOI: 10.1186/1471-2458-13-502
Source DB: PubMed Journal: BMC Public Health ISSN: 1471-2458 Impact factor: 3.295
Inclusion/exclusion criteria
| • Age 18 years and older | |
| • Medical diagnosis of HIV-1 positive serostatus | |
| • Sedentary lifestyle: not actively exercising ≥ 3 d · wk-1 for 20 min per session | |
| • Stable, DHHS-approved ART regimen for previous 3 months, with HIV viral load below 75 copies/mL | |
| • Capable of performing the required exercise regimen | |
| • Have daily access to a telephone for approximately 10 months | |
| • Capacity and willingness to provide informed consent and accept randomized group assignment | |
| • Individuals who have a clinical history strongly suggestive of Type 1 diabetes. | • Total cholesterol ≥240 mg/dl with LDL-C ≥160 mg/dl or TG levels ≥300 mg/dl. Note: Individuals on cholesterol lowering medications but meeting blood lipid requirements are eligible. |
| • History of serious arrythmias, cardiomyopathy, congestive heart failure, stroke or transient ischemic cerebral attacks, peripheral vascular disease with intermittent claudication, myocardial infarction, or CABG. | • Resting blood pressure >160 systolic and/or 90 diastolic. Note: Individuals on blood pressure medications but meeting blood pressure criteria are eligible. |
| • Malignancies in the past 5 years, except therapeutically controlled skin cancer. | • HbA1c ≥11%. Individuals whose HbA1c exceeds this level will be recommended to seek treatment immediately. Such individuals may be re-screened after three months to re-assess HbA1c eligibility. |
| • Plans to be away > 4 weeks in the next 9 months. | • Current opportunistic infection at the time of screening. |
| • Score of 5 or greater on the DAST or MAST (signifying excessive use of drugs or alcohol). | • Participation in another intervention trial. |
| • Weight loss in excess of 10% body weight in previous 12 weeks. | • Other temporary intervening event, such as sick spouse, bereavement, or recent move. |
| • Chronic or recurrent respiratory, gastrointestinal, neuromuscular, neurological, or psychiatric conditions. | |
| • Inflammatory-related conditions such as collagen disorders. | |
| • Any other medical condition or disease that is life-threatening or that can interfere with or be aggravated by exercise. | |
Figure 1Study flow chart.
Baseline characteristics of participants
| Gender, % (n) | |||
| Male | 47.1 (16) | 44.1 (15) | 45.6 (31) |
| Female | 52.9 (18) | 55.9 (19) | 54.4 (37) |
| Race, % (n) | |||
| White | 14.7 (5) | 8.8 (3) | 11.8 (8) |
| Black/African American | 79.4 (27) | 85.3 (29) | 82.4 (56) |
| >1 category | 2.9 (1) | 2.9 (1) | 2.9 (2) |
| Hispanic ethnicity, % (n) | |||
| Yes | 2.9 (1) | 5.9 (2) | 4.4 (3) |
| No | 97.1 (33) | 94.1 (32) | 95.6 (65) |
| Age in years, Mean ± SD | 49 ± 11 | 48 ± 10 | 48 ± 10 |
| Education, % (n) | |||
| Never attended school | 0 | 0 | 0 |
| Grades 1-8 | 0 | 0 | 0 |
| Grade 9-11 | 14.7 (5) | 14.7 (5) | 14.7 (10) |
| Grade 12 or GED | 23.5 (8) | 26.5 (9) | 25.0 (17) |
| Some college | 38.2 (13) | 44.1 (15) | 41.2 (28) |
| College grad | 23.5 (8) | 14.7 (5) | 19.1 (13) |
| Maritial status, % (n) | |||
| Married | 8.8 (3) | 11.8 (4) | 10.3 (7) |
| Divorced | 23.5 (8) | 11.8 (4) | 17.6 (12) |
| Widowed | 5.9 (2) | 8.8 (3) | 7.4 (5) |
| Separated | 11.8 (4) | 11.8 (4) | 11.8 (8) |
| Never married | 47.1 (16) | 32.4 (11) | 39.7 (27) |
| Couple/Significant Other | 2.9 (1) | 23.5 (8) | 13.2 (9) |
| Employment status, % (n) | |||
| Employed | 29.4 (10) | 44.1 (15) | 36.7 (25) |
| Not employed | 35.3 (12) | 20.6 (7) | 28.0 (19) |
| Student | 2.9 (1) | 5.9 (2) | 4.4 (3) |
| Retired | 2.9 (1) | 2.9 (1) | 2.9 (2) |
| Unable to work | 29.4 (10) | 20.6 (7) | 25.0 (17) |
| Income, % (n) | |||
| $0-9,999 | 29.4 (10 | 35.3 (12) | 32.4 (22) |
| $10,000- 19,999 | 26.5 (9) | 20.6 (7) | 23.5 (16) |
| $20,000- 29,999 | 14.7 (5) | 11.8 (4) | 13.2 (9) |
| $30,000- 39,999 | 5.9 (2) | 17.6 (6) | 11.8 (8) |
| $40,000- 49,999 | 2.9 (1) | 2.9 (1) | 2.9 (2) |
| $50,000- 59,999 | 0 | 2.9 (1) | 1.5 (1) |
| Prefer not to say | 20.6 (7) | 8.8 (3) | 14.7 (10) |
| Children in household, % (n) | |||
| 0 | 85.3 (29) | 76.5 (26) | 80.9 (55) |
| 1 | 2.9 (1) | 11.8 (4) | 7.4 (5) |
| 2 | 5.9 (2) | 5.9 (2) | 5.9 (4) |
| 3 | 0 | 2.9 (1) | 1.5 (1) |
| ≥ 4 | 5.9 (2) | 0 | 3 (2) |
| Weight in pounds, Mean ± SD | 191.48 ± 58.59 | 192.14 ± 49.38 | 191.81 ± 53.76 |
| BMI (kg/m2), Mean ± SD | 30.04 ± 8.38 | 30.79 ± 7.90 | 30.42 ± 8.09 |
| Waist circumference, Mean ± SD | 98.74 ± 20.96 | 99.22 ± 18.54 | 98.98 ± 19.63 |
| Blood Pressure, Mean ± SD | |||
| Systolic (mmHg) | 127 ± 16 | 130 ± 14 | 128 ± 15 |
| Diastolic (mmHg) | 83 ± 10 | 83 ± 10 | 83 ± 10 |
| Self-reported conditions %(n) | |||
| Heart condition | |||
| Yes | 0 | 0 | 0 |
| No | 100 (34) | 100 (34) | 100 (68) |
| Cancer | |||
| Yes | 2.9 (1) | 8.8 (3) | 6 (4) |
| No | 97.1 (33) | 91.2 (31) | 94 (64) |
| Diabetes | |||
| Yes | 5.8 (2) | 20.6 (7) | 13.2 (9) |
| No | 94.2 (32) | 79.4 (27) | 86.8 (59) |
| High Cholesterol | |||
| Yes | 36.4 (12) | 33.3 (11) | 34.8 (23) |
| No | 63.6 (21) | 66.7 (22) | 65.2 (43) |
| Hypertension | |||
| Yes | 45.5 (15) | 48.5 (16) | 47 (31) |
| No | 54.5 (18) | 51.5 (17) | 53 (35) |
| Sleep apnea | |||
| Yes | 17.6 (6) | 6.1 (2) | 11.9 (8) |
| No | 82.4 (28) | 93.9 (31) | 88.1 (59) |
| Arthritis | |||
| Yes | 20.6 (7) | 12.1 (4) | 16.4 (11) |
| No | 79.4 (27) | 87.9 (29) | 83.6 (56) |
| Hepatitis C | |||
| Yes | 17.6 (6) | 15.6 (5) | 16.7 (11) |
| No | 82.4 (28) | 84.4 (27) | 83.3 (55) |
| Fasting blood analysis, Mean ± SD | |||
| Cholsterol (mg/dL) | 188.89 ± 52.92 | 186.59 ± 38.55 | 187.76 ± 46.01 |
| Triglycerides (mg/dL) | 156.39 ± 146.87 | 130.59 ± 84.44 | 143.73 ± 119.95 |
| LDL (mg/dL) | 109.56 ± 35.98 | 107.41 ± 36.68 | 108.48 ± 36.00 |
| HDL (mg/dL) | 45.86 ± 20.58 | 52.96 ± 24.60 | 49.35 ± 22.71 |
| VLDL (mg/dL) | 26.19 ± 11.14 | 26.22 ± 16.90 | 26.20 ± 14.17 |
| Glucose (mg/dL) | 106.93 ± 48.22 | 111.33 ± 34.41 | 109.09 ± 41.69 |
| C-Reactive Protein (mg/L) | 4.76 ± 5.53 | 5.49 ± 5.96 | 5.12 ± 5.70 |
| Interleukin-6 (pg/mL) | 5.16 ± 7.11 | 4.07 ± 1.95 | 4.55 ± 4.88 |